{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"}],"units":"Participants"}],"description":"Participants who achieve a resolution or improvement in their ICANS. Complete response or partial response for ICANS is defined as either complete disappearance or decrease in the grade of severity as measured by ASTCT Consensus Grading for ICANS. The ASTCT grade is from 1 to 5 for ICANS with 1 being mild symptoms and 5 being severe symptoms.","groups":[{"description":"Patients who experience CRS/ICANS will receive this treatment\n\nSiltuximab: Siltuximab is administered at the dose of 11mg/kg via intravenous infusion over 1 hour. If no resolution of CRS is achieved then a repeat dose of siltuximab at the dose of 11mg/kg via intravenous infusion over 1 hour will be given.","id":"OG000","title":"Siltuximab"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Baseline through 28 days","title":"Participants With a Response for Immune Effector Cell Associated Neurotoxicity Syndrome (ICANS)","type":"SECONDARY","unitOfMeasure":"Participants"}